Drug Profile
Namilumab - Amgen/Izana Bioscience/Takeda
Alternative Names: AMG 203; Amg203; IZN 101; MT-203; MT03Latest Information Update: 30 Apr 2024
Price :
$50
*
At a glance
- Originator Micromet Inc
- Developer Izana Bioscience; Kinevant Sciences; Takeda Pharmaceuticals International GmbH
- Class Anti-inflammatories; Antipsoriatics; Antirheumatics; Monoclonal antibodies
- Mechanism of Action Granulocyte macrophage colony stimulating factor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Ankylosing spondylitis; Pulmonary sarcoidosis; Sarcoidosis
- No development reported COVID 2019 infections
- Discontinued Plaque psoriasis; Rheumatoid arthritis
Most Recent Events
- 25 Apr 2024 Roivant and Kinevant Sciences completes enrollment in the RESOLVE-Lung phase II trial in Sarcoidosis in USA and Europe (SC)
- 28 May 2023 No recent reports of development identified for clinical-Phase-Unknown development in COVID-2019-infections in Italy (Parenteral)
- 13 Dec 2022 Kinevant Sciences terminates phase-II RESOLVE-Heart trial in Sarcoidosis in USA (SC) due to sponsor business decision unrelated to safety (NCT05351554)